Cormorant Asset Management, LP Kura Oncology, Inc. Transaction History

Cormorant Asset Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$24.75 - $39.14 $16.1 Million - $25.4 Million	-650,000 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$29.0 - $41.62 $4.35 Million - $6.24 Million	150,000 Added 30.0%	650,000 $21.2 Million
Q3 2020 Nov 16, 2020	SELL	$16.3 - $30.64 $3.26 Million - $6.13 Million	-200,000 Reduced 28.57%	500,000 $15.3 Million
Q2 2020 Aug 14, 2020	SELL	$7.95 - $18.81 $795,000 - $1.88 Million	-100,000 Reduced 12.5%	700,000 $11.4 Million
Q1 2020 May 15, 2020	SELL	$6.45 - $14.04 $1.29 Million - $2.81 Million	-200,000 Reduced 20.0%	800,000 $7.96 Million
Q4 2019 Feb 14, 2020	SELL	$12.97 - $15.94 $3 Million - $3.69 Million	-231,500 Reduced 18.8%	1,000,000 $13.8 Million
Q3 2019 Nov 14, 2019	SELL	$14.75 - $20.87 $2.49 Million - $3.52 Million	-168,500 Reduced 12.04%	1,231,500 $18.7 Million
Q1 2019 May 15, 2019	BUY	$13.73 - $16.87 $11.7 Million - $14.3 Million	850,000 Added 154.55%	1,400,000 $23.2 Million
Q4 2018 Feb 14, 2019	BUY	$10.6 - $17.49 $5.83 Million - $9.62 Million	550,000 New	550,000 $7.72 Million

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $598M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.